
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5317932/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Invasive Assessment of Microvascular Resistance in Hypertrophic Cardiomyopathy With Echocardiographic Correlates. Heart Lung and Circulation, 2022, 31, 194-198.	0.4	4
2	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). Heart and Vessels, 2022, 37, 1291-1298.	1.2	3
3	Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. American Heart Journal, 2022, 251, 1-12.	2.7	4
4	Prognostic Role of Residual Thrombus Burden Following Thrombectomy: Insights From the TOTAL Trial. Circulation: Cardiovascular Interventions, 2022, 15, e011336.	3.9	4
5	Short Durations of Radial Hemostatic Device After Diagnostic Transradial Cardiac Catheterization: The PRACTICAL-2 Randomized Trial. Canadian Journal of Cardiology, 2021, 37, 276-283.	1.7	5
6	Association of Thrombus Aspiration With Time and Mortality Among Patients With ST-Segment Elevation Myocardial Infarction. JAMA Network Open, 2021, 4, e213505.	5.9	4
7	Contemporary use of guidelineâ€based higher potency P2Y12 receptor inhibitor therapy in patients with moderateâ€toâ€high risk nonâ€&Tâ€segment elevation myocardial infarction: Results from the Canadian ACS reflective II crossâ€sectional study. Clinical Cardiology, 2021, 44, 839-847.	1.8	3
8	Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010458.	3.9	2
9	Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS: Randomized Substudy of the Prospective Canadian ACS Reflective II Study. CJC Open, 2021, 3, 1463-1470.	1.5	1
10	Postprocedural Radial Artery Compression Time In Chronic AnticoaguLated patients using StatSeal: The PRACTICAL-SEAL study. International Journal of Cardiology, 2021, 346, 14-17.	1.7	0
11	Upstream anticoagulation for patients with STâ€elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the TOTAL trial. Catheterization and Cardiovascular Interventions, 2020, 96, 519-525.	1.7	5
12	Endothelial Dysfunction Is Not Associated With Spontaneous Coronary Artery Dissection. Cardiovascular Revascularization Medicine, 2020, 21, 1539-1541.	0.8	4
13	Radial versus femoral approach for rotational atherectomy. Coronary Artery Disease, 2020, 31, 393-395.	0.7	3
14	Nonculprit Lesion Plaque Morphology in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2020, 13, e008768.	3.9	63
15	ls Fractional Flow Reserve Useful in Assessing Coronary Artery Fistula: A Case-Based Discussion and Review. Heart Lung and Circulation, 2019, 28, e51-e53.	0.4	1
16	Cellular and molecular approaches to enhance myocardial recovery after myocardial infarction. Cardiovascular Revascularization Medicine, 2019, 20, 351-364.	0.8	8
17	Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial. Canadian Journal of Cardiology, 2019, 35, 1377-1385.	1.7	24
18	Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. BMJ: British Medical Journal, 2019, 367, 15476.	2.3	66

#	Article	IF	CITATIONS
19	Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine, 2019, 381, 1411-1421.	27.0	542
20	Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes. European Heart Journal, 2019, 40, 1188-1197.	2.2	275
21	Familial Spontaneous Coronary Artery Dissection and the SMAD-3 Mutation. American Journal of Cardiology, 2019, 124, 313-315.	1.6	14
22	Improving Electrocardiography Diagnostic Accuracy in Emergency Medical Services Personnel. CJC Open, 2019, 1, 28-34.	1.5	2
23	Hybrid Coronary Revascularization Versus Offâ€Pump Coronary Artery Bypass Grafting: Comparative Effectiveness Analysis With Longâ€Term Followâ€up. Journal of the American Heart Association, 2019, 8, e014204.	3.7	27
24	Radial versus femoral approach for saphenous vein grafts angiography and interventions. American Heart Journal, 2019, 210, 1-8.	2.7	11
25	Radial versus femoral approach for left ventricular endomyocardial biopsy. EuroIntervention, 2019, 15, 678-684.	3.2	10
26	Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. Journal of Thrombosis and Thrombolysis, 2018, 45, 225-233.	2.1	10
27	Radial versus femoral approach for sameâ€day interâ€facility transfer for percutaneous coronary intervention. Journal of Interventional Cardiology, 2018, 31, 230-235.	1.2	4
28	The Presence of a CTO in a Non–Infarct-Related Artery During a STEMI Treated With Contemporary Primary PCI Is Associated With Increased Rates of EarlyAand Late Cardiovascular Morbidity and Mortality. JACC: Cardiovascular Interventions, 2018, 11, 709-711.	2.9	23
29	Antithrombotic therapy in patients receiving saphenous vein coronary artery bypass grafts: a protocol for a systematic review and network meta-analysis. BMJ Open, 2018, 8, e019555.	1.9	2
30	Heparin use for diagnostic cardiac catheterization with a radial artery approach: An international survey of practice patterns. Catheterization and Cardiovascular Interventions, 2018, 92, 854-859.	1.7	7
31	Transradial-Guided Percutaneous Transaxillary Intra-aortic Balloon Pump Insertion. Canadian Journal of Cardiology, 2018, 34, 92.e5-92.e7.	1.7	2
32	Intravascular imaging for cardiac arrest with "normal―coronary arteriography. Cardiovascular Revascularization Medicine, 2018, 19, 53-55.	0.8	2
33	Renal denervation therapy beyond resistant hypertension. Journal of Thoracic Disease, 2018, 10, 707-713.	1.4	10
34	An atypical presentation of acute coronary syndrome. Journal of Thoracic Disease, 2018, 10, E616-E619.	1.4	0
35	Reason and Timing for Conversion to Sternotomy in Robotic-Assisted Coronary Artery Bypass Grafting and Patient Outcomes. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2018, 13, 423-427.	0.9	8
36	Thrombus Aspiration in Patients With High Thrombus Burden in the TOTAL Trial. Journal of the American College of Cardiology, 2018, 72, 1589-1596.	2.8	67

#	Article	IF	CITATIONS
37	Elevated level of lecithin:cholesterol acyltransferase (LCAT) is associated with reduced coronary atheroma burden. Atherosclerosis, 2018, 276, 131-139.	0.8	14
38	Pre-operative use of aspirin in patients undergoing coronary artery bypass grafting: a systematic review and updated meta-analysis. Journal of Thoracic Disease, 2018, 10, 3444-3459.	1.4	9
39	Transradial Approach for Left Ventricular Endomyocardial Biopsy. Canadian Journal of Cardiology, 2018, 34, 1283-1288.	1.7	6
40	Physicians' Attitudes Towards Anticoagulation for Prevention and Treatment of Left Ventricular Thrombus Following Anterior Myocardial Infarction. Canadian Journal of Cardiology, 2018, 34, 1089.e11-1089.e12.	1.7	2
41	Healing of latrogenic Coronary Dissection and Intramural Hematoma: Insights From OCT. Journal of Invasive Cardiology, 2018, 30, E12-E13.	0.4	3
42	Longâ€ŧerm outcome following remote ischemic postconditioning during percutaneous coronary interventions—the <scp>RIPâ€PCI</scp> trial longâ€ŧerm followâ€up. Clinical Cardiology, 2017, 40, 268-274.	1.8	11
43	Randomized Trial of Compression Duration After Transradial Cardiac Catheterization and Intervention. Journal of the American Heart Association, 2017, 6, .	3.7	26
44	A review of strategies for infarct size reduction during acute myocardial infarction. Cardiovascular Revascularization Medicine, 2017, 18, 374-383.	0.8	10
45	Effect of Ticagrelor VersusÂClopidogrel on Vascular Reactivity. Journal of the American College of Cardiology, 2017, 69, 2246-2248.	2.8	18
46	Is the Future of Coronary Arterial Revascularization a Hybrid Approach?. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2017, 12, 82-86.	0.9	19
47	Recurrent MI and stroke post–acute coronary syndrome: Which is the lesser evil?. American Heart Journal, 2017, 187, 191-193.	2.7	1
48	Bare metal versus drug eluting stents for ST-segment elevation myocardial infarction in the TOTAL trial. International Journal of Cardiology, 2017, 248, 120-123.	1.7	3
49	Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. American Heart Journal, 2017, 192, 105-112.	2.7	35
50	Radiotherapy-Induced Cardiac Implantable Electronic Device Dysfunction in Patients With Cancer. American Journal of Cardiology, 2017, 119, 284-289.	1.6	36
51	Ischemic postconditioning during primary percutaneous coronary interventions—not ready for prime time. Journal of Thoracic Disease, 2017, 9, 2752-2755.	1.4	1
52	Shedding light on stent thrombosis. Journal of Thoracic Disease, 2017, 9, 4903-4907.	1.4	2
53	Association Between Administration of Ticagrelor and Microvascular Endothelial Function. JAMA Cardiology, 2017, 2, 1042.	6.1	7
54	Effects of hypertonic saline solution on body weight and serum creatinine in patients with acute decompensated heart failure. World Journal of Cardiology, 2017, 9, 685.	1.5	16

#	Article	IF	CITATIONS
55	Nitroglycerin-Derived Pd/Pa for the Assessment of Intermediate Coronary Lesions. Journal of Invasive Cardiology, 2017, 29, E177-E183.	0.4	1
56	Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 3, qcw051.	4.0	5
57	Optical Coherence Tomography–Guided Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2016, 9, e003414.	3.9	37
58	Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. American Heart Journal, 2016, 180, 82-89.	2.7	19
59	Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT). American Heart Journal, 2016, 181, 26-34.	2.7	16
60	The effect of fresh versus standard blood transfusion on microvascular endothelial function. American Heart Journal, 2016, 181, 156-161.	2.7	13
61	Association of endothelial dysfunction and no-reflow during primary percutaneous coronary intervention for ST-elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2016, 17, 552-555.	0.8	7
62	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. Canadian Journal of Cardiology, 2016, 32, 1221.e11-1221.e18.	1.7	7
63	Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet, The, 2016, 387, 127-135.	13.7	187
64	The Impact of Peripheral Nerve Stimulation on Coronary Blood Flow and Endothelial Function. Cardiovascular Drugs and Therapy, 2015, 29, 527-533.	2.6	4
65	Culprit lesion thrombus burden after manual thrombectomy or percutaneous coronary intervention-alone in ST-segment elevation myocardial infarction: the optical coherence tomography sub-study of the TOTAL (ThrOmbecTomy versus PCI ALone) trial. European Heart Journal, 2015, 36, 1892-1900.	2.2	60
66	Clinical Outcomes of Treatment by Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery in Patients With Chronic Kidney Disease Undergoing Index Revascularization in Ontario. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	42
67	Biodegradable Stent Platforms: Are We Heading in the Right Direction?. Canadian Journal of Cardiology, 2015, 31, 957-959.	1.7	2
68	Out-of-Hospital Cardiac Arrest and Acute Coronary Syndromes: Reviewing Post-Resuscitation Care Strategies. Canadian Journal of Cardiology, 2015, 31, 1477-1480.	1.7	8
69	Clinical presentation and outcome of patients with ST-segment elevation myocardial infarction without culprit angiographic lesions. Cardiovascular Revascularization Medicine, 2015, 16, 217-220.	0.8	3
70	Heart Block and Temporary Pacing During Rotational Atherectomy. Canadian Journal of Cardiology, 2015, 31, 335-340.	1.7	15
71	Multimodality Imaging for Assessment of Coronary Embolus. Canadian Journal of Cardiology, 2015, 31, 364.e7.	1.7	1
72	Takayasu arteritis involving the left main coronary artery treated with a bioresorbable vascular scaffold. International Journal of Cardiology, 2015, 190, 1-3.	1.7	5

#	Article	IF	CITATIONS
73	Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. New England Journal of Medicine, 2015, 372, 1389-1398.	27.0	536
74	One-year outcome of the sevoflurane in acute myocardial infarction randomized trial. Canadian Journal of Anaesthesia, 2015, 62, 1279-1286.	1.6	4
75	Short-term outcomes in patients with acute coronary syndrome treated with direct bioresorbable scaffold deployment. Cardiovascular Revascularization Medicine, 2015, 16, 381-385.	0.8	2
76	Ultrasound guidance for vascular access in patients undergoing coronary angiography via the transradial approach. Journal of Invasive Cardiology, 2015, 27, 163-6.	0.4	2
77	Remote Ischemic Postconditioning During Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2014, 7, 225-232.	3.9	45
78	Sevoflurane in acute myocardial infarction: A pilot randomized study. American Heart Journal, 2014, 168, 776-783.	2.7	10
79	Diagnostic accuracy of ST-segment elevation myocardial infarction by various healthcare providers. International Journal of Cardiology, 2014, 177, 825-829.	1.7	17
80	Design and rationale of the TOTAL trial: A randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. American Heart Journal, 2014, 167, 315-321.e1.	2.7	66
81	Bioresorbable vascular scaffold implantation for treatment of recurrent in-stent restenosis: Insights from optical coherence tomography. International Journal of Cardiology, 2014, 172, 238-239.	1.7	7
82	Sedation, Analgesia, and Anaesthesia Variability in Laboratory-Based Cardiac Procedures: An International Survey. Canadian Journal of Cardiology, 2014, 30, 627-633.	1.7	27
83	Untreated preoperative depression is not associated with postoperative arrhythmias in CABG patients. Canadian Journal of Anaesthesia, 2014, 61, 12-18.	1.6	3
84	Left Main Coronary Artery Percutaneous Coronary Intervention in High-Risk Patients: Hopes for Improvement and Limitations of Randomized Trials. Canadian Journal of Cardiology, 2014, 30, 1256-1258.	1.7	0
85	Cardiac catheterization is associated with superior outcomes for survivors of out of hospital cardiac arrest: Review and meta-analysis. Resuscitation, 2014, 85, 1533-1540.	3.0	128
86	Response to Letter Regarding Article, "Remote Ischemic Postconditioning During Percutaneous Coronary Interventions: Remote Ischemic Postconditioning-Percutaneous Coronary Intervention Randomized Trial― Circulation: Cardiovascular Interventions, 2014, 7, 423-423.	3.9	2
87	Illuminating and Alarming Insights Into Vascular Healing. Canadian Journal of Cardiology, 2014, 30, 855-857.	1.7	5
88	Contrast Volume Use in Manual vs Automated Contrast Injection Systems for Diagnostic Coronary Angiography and Percutaneous Coronary Interventions. Canadian Journal of Cardiology, 2013, 29, 372-376.	1.7	12
89	The impact of industry representative's visits on utilization of coronary stents. American Heart Journal, 2013, 166, 258-265.	2.7	19
90	An international survey of clinical practice during primary percutaneous coronary intervention for ST-elevation myocardial infarction with a focus on aspiration thrombectomy. EuroIntervention, 2013, 8, 1143-1148.	3.2	12

#	Article	IF	CITATIONS
91	Perioperative Management of Antiplatelet Agents in Patients Undergoing Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2012, 26, 680-686.	1.3	7
92	Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial. American Heart Journal, 2012, 163, 176-181.e2.	2.7	5
93	Inhibition of sPLA2 and Endothelial Function: A Substudy of the SPIDER-PCI Trial. Canadian Journal of Cardiology, 2012, 28, 215-221.	1.7	3
94	Conditioning of the heart: From pharmacological interventions to local and remote protection. International Journal of Cardiology, 2011, 146, 311-318.	1.7	31
95	Remote ischemic conditioning $\hat{a} \in$ " The unknown. International Journal of Cardiology, 2011, 150, 96.	1.7	1
96	Melatonin and myocardial protection. International Journal of Cardiology, 2011, 150, 207.	1.7	2
97	Response to Letter Regarding Article, "The sPLA <sub>2</sub> Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial― Circulation, 2011, 124, .	1.6	0
98	Remote ischaemic conditioning before exercise: are we there yet?. Heart, 2011, 97, 1284-1285.	2.9	5
99	Selective use of embolic protection devices during saphenous vein grafts interventions: A singleâ€center experience. Catheterization and Cardiovascular Interventions, 2010, 75, 1037-1044.	1.7	9
100	The sPLA <sub>2</sub> Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial. Circulation, 2010, 122, 2411-2418.	1.6	27
101	Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. European Heart Journal, 2010, 31, 1142-1148.	2.2	605
102	Ventricular septal rupture following acute myocardial infarction. Canadian Journal of Cardiology, 2010, 26, 179.	1.7	0
103	The Adverse Long-Term Impact of Renal Impairment in Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stent Era. Circulation: Cardiovascular Interventions, 2009, 2, 309-316.	3.9	53
104	Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques. Heart, 2009, 95, 1525-1530.	2.9	100
105	Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy. Atherosclerosis, 2009, 207, 111-115.	0.8	27
106	Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Current Atherosclerosis Reports, 2008, 10, 230-235.	4.8	23
107	Sex differences in vascular and endothelial responses to acute mental stress. Clinical Autonomic Research, 2008, 18, 339-345.	2.5	49
108	Association Between the Paraoxonase-1 192Q>R Allelic Variant and Coronary Endothelial Dysfunction in Patients With Early Coronary Artery Disease. Mayo Clinic Proceedings, 2008, 83, 158-164.	3.0	6

#	Article	IF	CITATIONS
109	Hyperglycemia during acute myocardial infarction in patients who are treated by primary percutaneous coronary intervention: Impact on long-term prognosis. International Journal of Cardiology, 2008, 123, 117-122.	1.7	30
110	Transient hyperglycemia in patients with acute myocardial infarction: Time to define optimal glucose levels. International Journal of Cardiology, 2008, 130, 474.	1.7	0
111	The Interaction Between Coronary Endothelial Dysfunction, Local Oxidative Stress, and Endogenous Nitric Oxide in Humans. Hypertension, 2008, 51, 127-133.	2.7	126
112	Response to Endothelial Dysfunction, Isoprostanes, and Copper Deficiency. Hypertension, 2008, 52, .	2.7	1
113	Hormonal and Volume Dysregulation in Women With Premenstrual Syndrome. Hypertension, 2008, 51, 1225-1230.	2.7	53
114	Association Between the Paraoxonase-1 192Q>R Allelic Variant and Coronary Endothelial Dysfunction in Patients With Early Coronary Artery Disease. Mayo Clinic Proceedings, 2008, 83, 158-164.	3.0	9
115	Local Production of Lipoprotein-Associated Phospholipase A 2 and Lysophosphatidylcholine in the Coronary Circulation. Circulation, 2007, 115, 2715-2721.	1.6	221
116	Effect of aging on the cardiovascular regulatory systems in healthy women. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R788-R793.	1.8	89
117	Smoking Is Associated With Epicardial Coronary Endothelial Dysfunction and Elevated White Blood Cell Count in Patients With Chest Pain and Early Coronary Artery Disease. Circulation, 2007, 115, 2621-2627.	1.6	118
118	Severe myalgia associated with propofol sedation. European Journal of Anaesthesiology, 2007, 24, 92.	1.7	1
119	Coronary endothelial dysfunction and hyperlipidemia are independently associated with diastolic dysfunction in humans. American Heart Journal, 2007, 153, 1081-1087.	2.7	33
120	Lipoprotein-Associated Phospholipase A2. Molecular Diagnosis and Therapy, 2007, 11, 219-226.	3.8	19
121	The effect of drug eluting stents on cardiovascular events in patients with intermediate lesions and borderline fractional flow reserve. Catheterization and Cardiovascular Interventions, 2007, 70, 525-531.	1.7	25
122	New Frontiers in the Evaluation of Cardiac Patients for Noncardiac Surgery. Anesthesiology, 2007, 107, 1018-1028.	2.5	11
123	Impaired cerebral CO <sub>2</sub> vasoreactivity: association with endothelial dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H1856-H1861.	3.2	182
124	The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients. Journal of Invasive Cardiology, 2005, 17, 296-9.	0.4	6
125	Role of Nitric Oxide in the Regulation of Cerebral Blood Flow in Humans. Circulation, 2003, 107, 1901-1905.	1.6	118
126	Unusual Cause of Partially Reversible Severe Cardiovascular Autonomic Failure. American Journal of the Medical Sciences, 2003, 326, 159-163.	1.1	4

#	Article	IF	CITATIONS
127	Abnormal melatonin secretion in hypogonadal men: the effect of testosterone treatment. Clinical Endocrinology, 1997, 47, 463-469.	2.4	25
128	Abnormal melatonin secretion in male patients with hypogonadism. Journal of Molecular Neuroscience, 1996, 7, 91-98.	2.3	23
129	Decreased nocturnal melatonin secretion in patients with Klinefelter's syndrome. Clinical Endocrinology, 1996, 45, 749-754.	2.4	13
130	Nocturnal melatonin and luteinizing hormone rhythms in women with hyperprolactinemic amenorrhea. Journal of Pineal Research, 1996, 20, 72-78.	7.4	5
131	Nocturnal secretory patterns of melatonin, luteinizing hormone, prolactin and Cortisol in male patients with gonadotropin-releasing hormone deficiency. Journal of Pineal Research, 1996, 21, 49-54.	7.4	11
132	Testosterone treatment alters melatonin concentrations in male patients with gonadotropin-releasing hormone deficiency. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 770-774.	3.6	24
133	Increased nocturnal melatonin secretion in male patients with hypogonadotropic hypogonadism and delayed puberty. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2144-2148.	3.6	34